We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.
- Authors
Frishman, William H.; Henderson, Linda S.; Lukas, Mary Ann
- Abstract
Cardiovascular disease is the leading cause of death worldwide. Within the treatment armamentarium, beta-blockers have demonstrated effi cacy across the spectrum of cardiovascular disease - from modifi cation of a risk factor (ie, hypertension) to treatment after an acute event (ie, myocardial infarction). Recently, the use of beta-blockers as a fi rst-line therapy in hypertension has been called into question. Moreover, beta-blockers as a class are saddled with a misperception of having poor tolerability. However, vasodilatory beta-blockers such as carvedilol have a different hemodynamic action that provides the benefi ts of beta-blockade with the addition of vasodilation resulting from alpha 1-adrenergic receptor blockade. Vasodilation reduces total peripheral resistance, which may produce an overall positive effect on tolerability. Recently, a new, controlled-release carvedilol formulation has been developed that provides the clinical effi cacy of carvedilol but is indicated for once-daily dosing. This review presents an overview of the clinical and pharmacologic carvedilol controlled-release data.
- Publication
Vascular Health & Risk Management, 2008, Vol 4, Issue 6, p1387
- ISSN
1176-6344
- Publication type
Article